Imiquimod enhances anti-tumor effects of CD47 targeting in oral squamous cell carcinoma.

Researchers are investigating a new way to treat oral squamous cell carcinoma, a common type of mouth cancer. They found that pairing a medication called imiquimod with a treatment known as CD47-targeted therapy significantly improves the body's ability to clear away these cancer cells.

To understand how this works, think of macrophages as the cleanup crew of the immune system. Their job is to swallow and destroy harmful cells, a process called phagocytosis. The researchers discovered that imiquimod triggers a specific communication channel in these cells called the TLR7-NF-kappaB pathway. This switches the macrophages into an aggressive, tumor-fighting state known as M1 polarization. When combined with the CD47-targeted therapy, the immune cells become highly effective at eating the oral cancer cells.

Tests in living models showed that applying imiquimod directly to the local area is biologically safe and effectively boosts the CD47 treatment. However, this research is still in its early stages. The current findings rely entirely on laboratory and animal models. Scientists have not yet conducted human clinical trials or released specific numerical data on the treatment outcomes.